Microbot Medical Inc. (NASDAQ:MBOT) Receives Average Rating of “Buy” from Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have earned a consensus rating of “Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.6250.

A number of research analysts have weighed in on MBOT shares. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a research note on Tuesday, July 14th. Loop Capital set a $4.00 price objective on Microbot Medical in a research note on Wednesday, June 3rd. Zacks Research raised Microbot Medical from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a report on Wednesday, July 8th. Finally, Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. DNB Asset Management AS lifted its position in shares of Microbot Medical by 178.1% in the fourth quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 433,869 shares during the last quarter. Man Group plc bought a new stake in Microbot Medical in the 4th quarter valued at $35,000. Squarepoint Ops LLC raised its stake in Microbot Medical by 102.6% in the 4th quarter. Squarepoint Ops LLC now owns 24,526 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 12,419 shares during the period. Renaissance Technologies LLC acquired a new stake in Microbot Medical during the 4th quarter valued at $49,000. Finally, Zacks Investment Management acquired a new stake in Microbot Medical during the 3rd quarter valued at $33,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Price Performance

Shares of NASDAQ MBOT opened at $1.77 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 22.59 and a quick ratio of 21.93. The business has a 50-day moving average of $1.84 and a 200-day moving average of $2.08. The stock has a market capitalization of $118.89 million, a price-to-earnings ratio of -6.81 and a beta of 1.06. Microbot Medical has a fifty-two week low of $1.60 and a fifty-two week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts predict that Microbot Medical will post -0.28 earnings per share for the current fiscal year.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.